1. Home > Latest Topics >

Question 4: Levofloxacin in community-acquired pneumonia trials

20 June, 2018

Question 4
Levofloxacin has been used in CAP trials compared with ceftriaxone, with or without cefuroxime axetil; with amoxicillin-clavulanic acid; and gatifloxacin. Could you discuss the results of these trials?


LATEST TOPICS

Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024
Managing severe infections: Practical approaches for antibiotic use, including combination therapy
05 March, 2024
Updating Traditional Approaches: Expert Insights on Addressing Urinary Tract Infections
26 February, 2024
Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024

RELATED ARTICLES

Community-acquired pneumonia: Insights into macrolide resistance and a review of levofloxacin use
05 July, 2021
Changes and Updates in the New ATS/IDSA 2019 CAP Guidelines
06 May, 2021
Should we use and how to use anti-bacterial drugs for Covid-19 infection?
10 April, 2023
CAP in elderly: Diagnosis challenges and optimisation of antimicrobial therapy
24 June, 2021
Combination antibiotic therapy for penicillin non-susceptible Streptococcus pneumoniae
14 February, 2023